A Randomised, Double-Blind, Placebo Controlled, Multi-Center Study To Investigate The Use Of Mepolizumab (Sb-240563) In Reducing The Need For Surgery In Subjects With Severe Bilateral Nasal Polyposis
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
Price : $35 *
At a glance
- Drugs Mepolizumab (Primary)
- Indications Nasal polyps
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by Clinical trial.gov record.
- 06 Nov 2014 Planned End Date changed from 1 Aug 2014 to 1 Nov 2014 as reported by Clinical trial.gov record.